Skip to main content
Premium Trial:

Request an Annual Quote

Cellzome Achieves Second Milestone in GSK Collaboration

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German chemical proteomics firm Cellzome said today that it has hit a second milestone in its ongoing epigentics collaboration with GlaxoSmithKline.

The firm did not disclose the amount of the payment, but said that it comes only two months after the firm achieved a first milestone in the collaboration.

As GenomeWeb Daily News reported in early 2010, GSK paid €33 million ($45 million) up front for exclusive access to Cellzome's Episphere for epigenetic research on immunoinflammatory disease. Cellzome could be eligible for milestone payments of over €475 million, the firms said at the time.

"Achieving the second milestone in this collaboration in less than a year after its start demonstrates how well our technology is suited to address drug discovery for epigenetic targets," Cellzome CEO Tim Edwards said in a statement.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.